2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
| 热门AI工具： |
论文引言生成
New
AI 写作痕迹检测
Hot
学术改写降重
论文摘要生成
参考文献挖掘工具
审稿意见辅助撰写
|
查看更多AI工具 >> |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | LANCET ONCOLOGY LANCET ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.8
51人评分
我要评分
声誉 10.0 影响力 9.7 速度 9.3 | |||||||||||||||||
| 期刊ISSN | 1470-2045 | 安装APP，查看期刊最新消息
| ||||||||||||||||
| E-ISSN | 1474-5488 | |||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||
| 实时影响因子 | 截止2026年9月20日：21.21 | |||||||||||||||||
| 2025-2026自引率 | 1.8%点击查看自引率趋势图 | |||||||||||||||||
| 五年IF （数据来源于网友提供） | 40.504数据由网友[alphaoak803]收集提供 | |||||||||||||||||
| h-index | 274 | |||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||
| 期刊简介 |
| |||||||||||||||||
| 期刊官方网站 | http://www.thelancet.com/journals/lanonc/issue/current | |||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/THELANCETONCOLOGY | |||||||||||||||||
| 该期刊中国学者近期发文 - New | Adjuvant alectinib versus chemotherapy in resected ALK- positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial Author: Dziadziuszko, Rafal; Ahn, Jin Seok; Barlesi, Fabrice; Solomon, Benjamin J.; Wu, Yi-Long; Bondarenko, Igor; Hochmair, Maximilian; Horinouchi, Hidehito; Lee, Dae Ho; Lee, Jong-Seok; Planchard, David; Rittmeyer, Achim; Zhong, Wenzhao; Adler, Leah; Archer, Venice; Cardona, Andres; Petric, Patricia; Scalori, Astrid; Ding, Beiying; Mamolo, Carla; Smoljanovic, Vlatka; Nishio, Makoto Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 9, pp. 1110-1119. DOI: 10.1016/S1470-2045(26)00283-4 Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, doubleblind, placebo-controlled, phase 3 trial Author: Gao, Ming; Park, Young Joo; Lin, Chia-Chi; Krzyzanowska, Monika K.; Li, Zhiyong; Tsai, Hui-Jen; Shi, Feng; Qin, Jianwu; Choong, Swee Hsia; Lin, Yansong; Zhang, Yuan; Kang, Jin H.; Hoff, Ana O.; Tan, Monique; Roughton, Michael; Paul, Michaela; Wirth, Lori J Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 8, pp. 994-1003. DOI: 10.1016/S1470-2045(26)00133-6 Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial Author: Yao, Herui; Zhang, Qingyuan; Li, Huiping; Yin, Yongmei; Wang, Shusen; Ouyang, Quchang; Sun, Tao; Li, Wei; Wang, Xiaojia; Yan, Min; Wang, Biyun; Cheng, Jing; Tong, Zhongsheng; Wei, Wei; Wang, Xinshuai; Xie, Weimin; Sun, Zhengkui; Yuan, Peng; Geng, Cuizhi; Gan, Lu; Han, Xinghua; Li, Wenfeng; Zhou, Shoubing; Yan, Xi; Gao, Jinnan; Yi, Tienan; Wu, Jingna; Niu, Zhaofeng; Fu, Fangmeng; Nie, Jianyun; Wang, Yongsheng; Zhao, Bing; Wu, Zhiyong; Zhu, Zhengqiu; Yang, Yaping; Zhao, Jianli; Sheng, Zhen; Zhang, Ying; Cheng, Lin; Zhu, Xiaoyu; Song, Erwei Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 8, pp. 929-940. DOI: 10.1016/S1470-2045(26)00193-2 Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2) an open-label, multicentre, randomised, phase 2trial Author: Hu, Huabin; Shen, Xutao; Li, Yunfeng; Zhou, Jiaming; Liu, Ping; Zhang, Jianwei; Hou, Yujie; Wang, Xiaozhong; Deng, Jiaye; Zheng, Zhuoxin; Li, Jianxia; Lan, Ping; Wu, Xiaojian; Kang, Liang; Huang, Meijin; He, Zhen; He, Xiaosheng; Yang, Zuli; Huang, Liang; Wang, Hui; Wang, Huaiming; Luo, Shuangling; Chen, Dianke; Xie, Xiaoyu; Zhang, Yan; Zhai, Xiaohui; Li, Shanshan; Li, Weiwei; Hu, Jiancong; Yang, Tao; Wang, Chao; Deng, Weihao; Huang, Yan; Cao, Wuteng; Li, Fangqian; Shi, Lishuo; Ling, Li; Deng, Yanhong Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 8, pp. 1020-1030. DOI: 10.1016/S1470-2045(26)00220-2 | |||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足LANCET ONCOLOGY的语言要求，还能让LANCET ONCOLOGY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被LANCET ONCOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||
| 通讯方式 | ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710 | |||||||||||||||||
| 出版商 | Lancet Publishing Group | |||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||
| 出版语言 | English | |||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||
| 出版年份 | 2000 | |||||||||||||||||
| 年文章数 | 174点击查看年文章数趋势图 | |||||||||||||||||
| Gold OA文章占比 | 16.03% | |||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 79.89% | |||||||||||||||||
| WOS期刊JCR分区 （ 2025-2026年最新版） | 注册或登录后，查看WOS分区等级 | |||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||
  | ||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1470-2045%5BISSN%5D | |||||||||||||||||
| 平均审稿速度 | 网友分享经验： 一般,3-8周 | |||||||||||||||||
| 平均录用比例 | 网友分享经验： 极难 | |||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在LANCET ONCOLOGY顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Adjuvant alectinib versus chemotherapy in resected ALK- positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial Author: Dziadziuszko, Rafal; Ahn, Jin Seok; Barlesi, Fabrice; Solomon, Benjamin J.; Wu, Yi-Long; Bondarenko, Igor; Hochmair, Maximilian; Horinouchi, Hidehito; Lee, Dae Ho; Lee, Jong-Seok; Planchard, David; Rittmeyer, Achim; Zhong, Wenzhao; Adler, Leah; Archer, Venice; Cardona, Andres; Petric, Patricia; Scalori, Astrid; Ding, Beiying; Mamolo, Carla; Smoljanovic, Vlatka; Nishio, Makoto Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 9, pp. 1110-1119. DOI: 10.1016/S1470-2045(26)00283-4 PubMed DOI |
| 2. | Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, doubleblind, placebo-controlled, phase 3 trial Author: Gao, Ming; Park, Young Joo; Lin, Chia-Chi; Krzyzanowska, Monika K.; Li, Zhiyong; Tsai, Hui-Jen; Shi, Feng; Qin, Jianwu; Choong, Swee Hsia; Lin, Yansong; Zhang, Yuan; Kang, Jin H.; Hoff, Ana O.; Tan, Monique; Roughton, Michael; Paul, Michaela; Wirth, Lori J Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 8, pp. 994-1003. DOI: 10.1016/S1470-2045(26)00133-6 PubMed DOI |
| 3. | Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial Author: Yao, Herui; Zhang, Qingyuan; Li, Huiping; Yin, Yongmei; Wang, Shusen; Ouyang, Quchang; Sun, Tao; Li, Wei; Wang, Xiaojia; Yan, Min; Wang, Biyun; Cheng, Jing; Tong, Zhongsheng; Wei, Wei; Wang, Xinshuai; Xie, Weimin; Sun, Zhengkui; Yuan, Peng; Geng, Cuizhi; Gan, Lu; Han, Xinghua; Li, Wenfeng; Zhou, Shoubing; Yan, Xi; Gao, Jinnan; Yi, Tienan; Wu, Jingna; Niu, Zhaofeng; Fu, Fangmeng; Nie, Jianyun; Wang, Yongsheng; Zhao, Bing; Wu, Zhiyong; Zhu, Zhengqiu; Yang, Yaping; Zhao, Jianli; Sheng, Zhen; Zhang, Ying; Cheng, Lin; Zhu, Xiaoyu; Song, Erwei Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 8, pp. 929-940. DOI: 10.1016/S1470-2045(26)00193-2 PubMed DOI |
| 4. | Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2) an open-label, multicentre, randomised, phase 2trial Author: Hu, Huabin; Shen, Xutao; Li, Yunfeng; Zhou, Jiaming; Liu, Ping; Zhang, Jianwei; Hou, Yujie; Wang, Xiaozhong; Deng, Jiaye; Zheng, Zhuoxin; Li, Jianxia; Lan, Ping; Wu, Xiaojian; Kang, Liang; Huang, Meijin; He, Zhen; He, Xiaosheng; Yang, Zuli; Huang, Liang; Wang, Hui; Wang, Huaiming; Luo, Shuangling; Chen, Dianke; Xie, Xiaoyu; Zhang, Yan; Zhai, Xiaohui; Li, Shanshan; Li, Weiwei; Hu, Jiancong; Yang, Tao; Wang, Chao; Deng, Weihao; Huang, Yan; Cao, Wuteng; Li, Fangqian; Shi, Lishuo; Ling, Li; Deng, Yanhong Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 8, pp. 1020-1030. DOI: 10.1016/S1470-2045(26)00220-2 PubMed DOI |
| 5. | Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials Author: Zhu, Youwen; Liu, Kun; Rosen, Steven T.; Liu, Wei; Zhu, Hong Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 7, pp. 893-902. DOI: 10.1016/S1470-2045(26)00086-0 PubMed DOI |
| 6. | Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases Author: Fan, Yu; Zhang, Huiru; Tang, Shan; Toi, Masakazu Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 7, pp. e325-e338. DOI: 10.1016/S1470-2045(26)00146-4 PubMed DOI |
| 7. | Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial Author: Li, Ziming; Hu, Jie; Chen, Jianhua; Yu, Yan; Meng, Xiangjiao; Dong, Xiaorong; Hu, Yanping; Ji, Yinghua; Liu, Haifeng; Wang, Weibo; Ning, Fangling; Zhang, Zhihong; Liu, Chunling; Zhang, Zhiye; Wang, Qiming; Zheng, Wei; Wang, Honghai; Qu, Xiujuan; Chen, Zhenming; Fan, Shaonan; Zhang, Xiaoqing; Lu, Shun Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 7, pp. 785-794. DOI: 10.1016/S1470-2045(26)00090-2 PubMed DOI |
| 8. | Brachytherapy capacity gaps and cancer control priorities Author: Wang, Hao; Hu, Yuanyuan; Li, Hui Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 6, pp. e271-e271. DOI: PubMed |
| 9. | International multisociety Delphi consensus for liver tumour thermal ablation: margin assessment Author: Paolucci, Iwan; Overduin, Christiaan G.; Johnston, Edward W.; Laimer, Gregor; Ahmed, Muneeb; Arellano, Ronald S.; Beerman, Marie; Beyer, Lukas P.; Breen, David J.; Burgmans, Mark C.; Calandri, Marco; Chern, Ming-Chih; Crocetti, Laura; van Dam, Ronald M.; Denys, Alban; Edwin, Bjorn; Filippiadis, Dimitrios; Fong, Yuman; Fotiadis, Nicos; Freedman, Jacob; Fretland, Asmund A.; Gimenez, Mariano; Garcia, Rodrigo G.; Grasso, Rosario F.; Helmberger, Thomas K.; Hendriks, Pim; Iezzi, Roberto; Jenniskens, Sjoerd F. M.; Kupferthaler, Alexander; Lachenmayer, Anja; Lee, Fred T., Jr.; Lee, Jeong M.; van der Lei, Susan; van der Leij, Christiaan; Liang, Ping; Lin, Charles C-W; Luerken, Lukas; Maglione, Manuel; Mahnken, Andreas; McWilliams, Justin P.; Menezes, Marcos; Narayanan, Govindarajan; Orsi, Franco; Pereira, Philippe L.; Pua, Uei; Puijk, Robbert S.; Rhim, Hyunchul; Rilling, William S.; Ruiter, Simeon J. S.; Ryan, Anthony G.; Schullian, Peter; Shyn, Paul B.; Siriwardena, Ajith K.; Smits, Maarten L. J.; Sofocleous, Constantinos T.; Solbiati, Luigi; Sotirchos, Vlasios; Staettner, Stefan; van Strijen, Marco; Syversveen, Trygve; Tinguely, Pascale; Tselikas, Lambros; Vauthey, Jean-Nicolas; Vogl, Thomas J.; Wah, Tze M.; White, Sarah B.; Wiggermann, Philipp; Wood, Bradford J.; van der Meulen, Jan; Goldberg, S. Nahum; Meijerink, Martijn R.; Bale, Reto; Odisio, Bruno C Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 5, pp. E248-E258. DOI: PubMed |
| 10. | International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards Author: Laimer, Gregor; Johnston, Edward W.; Overduin, Christiaan G.; Paolucci, Iwan; Ahmed, Muneeb; Arellano, Ronald S.; Beermann, Marie; Beyer, Lukas P.; Breen, David J.; Burgmans, Mark C.; Calandri, Marco; Chern, Ming-Chih; Crocetti, Laura; van Dam, Ronald M.; Denys, Alban; Edwin, Bjorn; Filippiadis, Dimitrios; Fong, Yuman; Fotiadis, Nicos; Freedman, Jacob; Fretland, Asmund A.; Gimenez, Mariano; Garcia, Rodrigo G.; Grasso, Rosario F.; Helmberger, Thomas K.; Hendriks, Pim; Iezzi, Roberto; Jenniskens, Sjoerd F. M.; Kupferthaler, Alexander; Lachenmayer, Anja; Lee, Fred T., Jr.; Lee, Jeong M.; van der Lei, Susan; van der Leij, Christiaan; Liang, Ping; Lin, Charles C-W; Luerken, Lukas; Maglione, Manuel; Mahnken, Andreas; McWilliams, Justin P.; Menezes, Marcos; Narayanan, Govindarajan; Orsi, Franco; Pereira, Philippe L.; Pua, Uei; Puijk, Robbert S.; Rhim, Hyunchul; Rilling, William S.; Ruiter, Simeon J. S.; Ryan, Anthony G.; Schullian, Peter; Shyn, Paul B.; Siriwardena, Ajith K.; Smits, Maarten L. J.; Sofocleous, Constantinos T.; Solbiati, Luigi; Sotirchos, Vlasios; Stattner, Stefan; van Strijen, Marco; Syversveen, Trygve; Tinguely, Pascale; Tselikas, Lambros; Vauthey, Jean-Nicolas; Vogl, Thomas J.; Wah, Tze M.; White, Sarah B.; Wiggermann, Philipp; Wood, Bradford J.; van der Meulen, Jan; Goldberg, S. Nahum; Meijerink, Martijn R.; Odisio, Bruno C.; Bale, Reto Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 5, pp. E259-E270. DOI: PubMed |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共42条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
